Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 19/20 | 0.58 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27732163 | 0.91 | NR1H4 (0.56) | NR1H4HSD17B13S1PR1 | |
| SCHEMBL1097119 | 0.88 | NR1H4 (0.61) | NR1H4HSD17B13 | |
| SCHEMBL21340364 | 0.87 | NR1H4 (0.57) | NR1H4HSD17B13S1PR1 | |
| SCHEMBL20094463 | 0.78 | NR1H4 (0.51) | NR1H4HSD17B13S1PR1 | |
| SCHEMBL4610396 | 0.78 | NR1H4 (0.56) | NR1H4HSD17B13 | |
| SCHEMBL29433179 | 0.77 | NR1H4 (0.60) | NR1H4HSD17B13 | |
| SCHEMBL1096074 | 0.77 | NR1H4 (0.60) | NR1H4HSD17B13 | |
| SCHEMBL22790384 | 0.76 | NR1H4 (0.45) | NR1H4HSD17B13 | |
| SCHEMBL1179604 | 0.75 | NR1H4 (0.53) | NR1H4HSD17B13 | |
| SCHEMBL29143491 | 0.75 | NR1H4 (0.85) | NR1H4HSD17B13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984360-B1 | Compounds and methods for modulating FX-receptors | LILLY CO ELI (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8153624-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2178851-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2010-06-17 | — | — | US | disclosed |
| EP-2178851-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | Eli Lilly & Company (US) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009012125-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, FXR1, SLC10A1 | NR1H4 1/4885HSD17B13 157/4885S1PR1 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.